Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose esketamine for prevention of postoperative delirium in burn surgery
ChiCTR2400090863Phase 4Completed
- Sponsor
- Ruijin Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in postoperative delirium (POD) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Incidence of postoperative delirium at 5 days after surgery. Started Oct 2024; status: completed.
02
Drugs
esketamine
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on ChiCTR2400090863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090863.